A Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of SEP 363856 in Subjects With Parkinson's Disease Psychosis .
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2018
At a glance
- Drugs SEP 363856 (Primary)
- Indications Parkinson's disease; Psychotic disorders
- Focus Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 06 Dec 2016 Status changed from not yet recruiting to recruiting.
- 09 Nov 2016 New trial record